Terns Pharmaceuticals Initiates a Phase 1 Clinical Trial of TERN-101

74

FOSTER CITY, Calif. & SHANGHAI–(BUSINESS WIRE)–Phase 1 study will evaluate the safety and tolerability of TERN-101, an FXR agonist in development for the treatment NASH …

 

http://www.businesswire.com/news/home/20190613005076/en/Terns-Pharmaceuticals-Initiates-Phase-1-Clinical-Trial/